866-997-4948(US-Canada Toll Free)

Selexipag (ACT-293987, NS-304) - Analysis and Forecasts from 2015 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 41 Pages


GlobalDatas pharmaceuticals report, Selexipag (ACT-293987, NS-304) Analysis and Forecasts from 2015 to 2020 provides Selexipag sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Selexipag including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Selexipag including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2015-2020 for Selexipag in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 5
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 6
2.4 Economic Impact of PAH 6
2.5 GlobalData Report Guidance 6

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10

4 Classification of PAH 12
4.1 Classification Based on Cause and Clinical Presentation 12
4.1.1 Idiopathic PAH 12
4.1.2 Familial PAH 12
4.1.3 Drug Induced PAH 12
4.1.4 PAH Associated with Other Conditions 12
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 12
4.2 Symptomatic Profile of PAH 12

5 Evolution of PAH Treatments 14

6 Medications 15
6.1 Prostanoids 15
6.1.1 Epoprostenol 15
6.1.2 Treprostinil 15
6.1.3 Iloprost 15
6.1.4 Beraprost 15
6.2 Endothelin Receptor Antagonists 16
6.2.1 Bosentan 16
6.2.2 Ambrisentan 16
6.2.3 Sitaxsentan 16
6.3 Phosphodiesterase Type 5 Inhibitors 16
6.3.1 Sildenafil 16
6.3.2 Tadalafil 16
6.4 Surgical Treatments 17
6.5 Investigational Combination Regimens 17
6.6 New Targets for PAH Therapy 18

7 Market Share by Class in PAH 20

8 Selexipag 21
8.1 Introduction 21
8.2 Mechanism of Action 21
8.3 Clinical Studies 21
8.3.1 Phase II 21
8.3.2 Phase III- GRIPHON 21
8.4 Milestones of Selexipag 22
8.5 Factors Affecting Sales of Selexipag 22
8.5.1 First in Class Drug 22
8.5.2 Dosing Compliance 22
8.5.3 Availability of Generics 22
8.6 Actelion / Nippon Shinyaku Alliance 22
8.7 Drug Evaluation 23
8.7.1 Drug Risk Benefit Score 23
8.7.2 Intensity of Competition 24
8.8 Sales Estimates 24
8.8.1 Target Patient Pool for Selexipag 24
8.8.2 Dosing 25
8.8.3 Market Penetration 25
8.8.4 Annual Cost of Therapy 25
8.8.5 Sales Projections of Selexipag 27

9 PAH Market: Appendix 36
9.1 Market Definitions 36
9.2 List of Abberiviations 36
9.3 Research Methodology 37
9.3.1 Coverage 37
9.3.2 Secondary Research 37
9.3.3 Forecasting 37
9.3.4 Number of Patients Approved to take the Drug 38
9.3.5 Net Penetration of Drug 38
9.3.6 Net Annual Dosing 39
9.3.7 Annual Cost of Therapy 39
9.3.8 Primary Research 39
9.3.9 Expert Panels 39
9.4 Drug Sales Estimates Model 40
9.5 Contact Us 40
9.6 Disclaimer 40
9.7 Sources 40

List of Table


Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (Phase III) 8
Table 3: PAH Drugs Evolution 14
Table 4: Milestones of Selexipag 22
Table 5: Drug Risk Benefit Score of Selexipag 23
Table 6: Safety and Tolerability of Selexipag in Comparison with Placebo 23
Table 7: Annual Cost of Therapy of Selexipag, 2015 26
Table 8: Selexipag, PAH, Global, Sales Forecasts ($m), 2015-2020 27
Table 9: Selexipag, PAH, The US, Sales Forecasts ($m), 20152020 28
Table 10: Selexipag, PAH, The UK, Sales Forecasts ($m), 20152020 29
Table 11: Selexipag, PAH, France, Sales Forecasts ($m), 20152020 30
Table 12: Selexipag, PAH, Germany, Sales Forecasts ($m), 20152020 31
Table 13: Selexipag, PAH, Italy, Sales Forecasts ($m), 20152020 32
Table 14: Selexipag, PAH, Spain, Sales Forecasts ($m), 20152020 33
Table 15: Selexipag, PAH, Japan, Sales Forecasts ($m), 2017-2020 34

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 20
Figure 3: Drug Model Diagram of Selexipag 25
Figure 4: Selexipag, PAH, Global, Sales Forecasts ($m), 2015-2020 27
Figure 5: Selexipag, PAH, The US, Sales Forecasts ($m), 20152020 28
Figure 6: Selexipag, PAH, The UK, Sales Forecasts ($m), 20152020 29
Figure 7: Selexipag, PAH, France, Sales Forecasts ($m), 20152020 30
Figure 8: Selexipag, PAH, Germany, Sales Forecasts ($m), 20152020 31
Figure 9: Selexipag, PAH, Italy, Sales Forecasts ($m), 20152020 32
Figure 10: Selexipag, PAH, Spain, Sales Forecasts ($m), 20152020 33
Figure 11: Selexipag, PAH, Japan, Sales Forecasts ($m), 2017-2020 34
Figure 12: Selexipag, PAH, Global, Sales Distribution by Country (%), 2020 35
Figure 13: Drug Model Diagram 38
Figure 14: Patients Approved for the Drug 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *